Učitavanje...
Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice
PURPOSE: Lenalidomide is used widely in B-cell malignancies for its immunomodulatory activity. It is primarily eliminated via the kidneys, with a significant proportion of renal elimination attributed to active processes. Lenalidomide is a weak substrate of P-glycoprotein (P-gp), though it is unclea...
Spremljeno u:
| Izdano u: | Cancer Chemother Pharmacol |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7375688/ https://ncbi.nlm.nih.gov/pubmed/31493176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03941-z |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|